If You Invested in Positron (POSC)

Positron Corporation (POSC) is a medical technology company in the surgical and medical instrument manufacturing industry. Traded on the OTC Markets under the symbol POSC, Positron focuses on molecular imaging medical devices, with a particular emphasis on Positron Emission Tomography (PET) and PET-CT imaging systems and related clinical services for nuclear medicine healthcare providers across North America.

The company describes itself as co-developing, manufacturing, and selling advanced PET and PET-CT imaging systems and integrated imaging solutions. These offerings combine molecular imaging hardware, software, and clinical and training services that support nuclear medicine practices, especially in cardiology and oncology. Positron specializes in cardiac Positron Emission Tomography (PET) imaging, which it characterizes as the gold standard in cardiac diagnostics and a key modality for accurately diagnosing coronary artery disease while supporting cost-effective medical practice.

Business focus and product portfolio

According to company disclosures, Positron’s business centers on PET and PET-CT systems and associated clinical services. Its product portfolio includes the Attrius® PET scanner, described as a 2D quantitative dedicated PET system optimized for nuclear cardiology, and the NeuSight PET-CT 64-slice scanner, which the company positions as a versatile PET-CT platform for both cardiac and oncology imaging. The Attrius system is designed to provide high-resolution cardiac imaging along with blood flow data suitable for coronary flow reserve analysis.

The NeuSight PET-CT system is described as offering high-performance anatomic and functional imaging for cardiology, oncology, and brain studies. Company materials highlight features such as a 72 cm wide-bore gantry aimed at patient comfort, high-sensitivity acquisition technology intended to reduce radiation exposure for patients and staff, and a compact, light-weight design that supports installation in a range of clinical environments. Positron states that its systems are engineered to support a broad spectrum of molecular imaging applications, including myocardial perfusion, tumor imaging, and neurological assessments.

Clinical services and practice solutions

In addition to hardware, Positron reports that it provides clinical services, technical support, and training to nuclear medicine and nuclear cardiology practices. The company describes its offerings as including clinical support services, practice solutions, and comprehensive support for system users. These services are intended to help healthcare providers implement cardiac PET and PET-CT imaging, optimize workflow, and apply advanced data acquisition and quantification tools, including applications for coronary flow reserve (CFR) and blood flow analysis.

Positron’s communications emphasize that its PET and PET-CT systems, combined with clinical and practice support, are aimed at helping physicians improve diagnostic accuracy, enhance patient outcomes, and manage costs in nuclear cardiology and oncology imaging. The company also notes that it offers a Prime Rental Program for NeuSight PET-CT scanners, which is designed to provide access to PET-CT technology through rental arrangements with cardiovascular diagnostic and treatment practices.

Market positioning and target customers

Positron describes itself as a molecular imaging medical device company and a provider of advanced imaging technology and services for nuclear cardiology and oncology. Its stated target customers include nuclear medicine healthcare providers, nuclear cardiology groups, cardiovascular diagnostic and treatment practices, and cardiology specialists focused on advanced cardiovascular diagnostics and interventional care. The company highlights multi-unit sales of PET-CT scanners and agreements for NeuSight PET-CT systems with nuclear cardiology and cardiovascular practices as examples of its market activity.

Company materials state that Positron’s PET and PET-CT systems, including Attrius PET and NeuSight PET-CT, are intended to facilitate the adoption of cardiac PET and support the growth of the nuclear imaging market. Positron also notes that its PET-CT systems are designed to serve the oncology imaging segment by providing high-resolution anatomic and functional imaging suitable for tumor and brain studies, in addition to cardiac applications.

Technology partnerships and development

Positron reports that it advances its technology through a co-developer, supplier, and research and development venture with Shenyang Intelligent Neuclear Technology Co., a subsidiary of Neusoft Medical Systems. The company also references an exclusive North American partnership with Neusoft Medical Systems in connection with its PET-CT product portfolio. Through these relationships, Positron states that it is working to expand its PET-CT offerings, including a planned PET-CT 4D molecular imaging device referred to as the Affinity PET-CT 4D 64-slice.

The company describes its PET-CT technologies as incorporating advanced data acquisition and identification capabilities that support faster, more precise scans and improved diagnostic confidence. It also emphasizes features such as data quantification and CFR applications as part of its technology suite for cardiac PET imaging.

Geographic footprint and headquarters

Positron indicates that it serves nuclear medicine healthcare providers throughout North America, and has referenced activity with practices across the United States, including expansion into the western U.S. The company has announced the establishment of a new corporate headquarters in the Buffalo–Niagara Falls region of New York, where it plans to house corporate operations, a product showroom, and a testing center. This facility is described as supporting growth initiatives, customer engagement, and operational capabilities for scaling PET-CT imaging solutions.

Regulatory status and SEC reporting

Positron has stated that it has become a reporting company with the U.S. Securities and Exchange Commission (SEC) through the filing of a Form 10 registration statement. As a result, the company indicates that it is subject to the reporting requirements of the Securities Exchange Act of 1934 and expects to file quarterly and annual reports, as well as current reports on material events. An 8-K filing notes that the company’s common stock, with a par value of $0.0001 per share, is registered under the symbol POSC on the OTC Markets.

In an 8-K filing, Positron also discloses a change in its independent registered public accounting firm, with the appointment of Salberg & Company, P.A. to audit its financial statements and review interim financial statements for specified quarters. Another 8-K describes a subscription agreement with an investor for the purchase of common stock shares in a private transaction relying on Regulation S under the Securities Act of 1933.

Capital raising and growth initiatives

The company has reported multiple equity financings, including capital raises of several million dollars through the issuance of common stock to investors. Positron states that these funds are intended to support commercial expansion, product development, regulatory activities, sales and marketing efforts, and broader strategic objectives in the PET-CT market. The company also links its capital raising activities to plans for SEC reporting, potential uplisting to a senior exchange, and expansion of its presence in North America with potential future access to European markets.

Across its public communications, Positron emphasizes its focus on expanding the use of cardiac and oncology PET modalities by delivering PET and PET-CT systems, clinical services, and practice solutions to nuclear medicine providers. The company positions its technology and services as tools for enabling accurate diagnosis of coronary artery disease, supporting nuclear cardiology programs, and addressing the imaging needs of oncology and neurological studies within nuclear medicine.